Department of General Medicine, Juntendo University Graduate School of Medicine, Bunkyo, Tokyo, Japan.
Department of Safety and Health Promotion, Juntendo University, Bunkyo, Tokyo, Japan.
Sci Rep. 2021 Apr 16;11(1):8380. doi: 10.1038/s41598-021-87688-9.
Healthcare workers (HCWs) are highly exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The actual coronavirus disease (COVID-19) situation, especially in regions that are less affected, has not yet been determined. This study aimed to assess the seroprevalence of SARS-CoV-2 in HCWs working in a frontline hospital in Tokyo, Japan. In this cross-sectional observational study, screening was performed on consented HCWs, including medical, nursing, and other workers, as part of a mandatory health checkup. The screening test results and clinical characteristics of the participants were recorded. The antibody seroprevalence rate among the 4147 participants screened between July 6 and August 21, 2020, was 0.34% (14/4147). There was no significant difference in the seroprevalence rate between frontline HCWs with a high exposure risk and HCWs working in other settings with a low exposure risk. Of those seropositive for SARS-CoV-2, 64% (9/14) were not aware of any symptoms and had not previously been diagnosed with COVID-19. In conclusion, this study provides insights into the extent of infection and immune status in HCWs in Japan, which has a relatively low prevalence of COVID-19. Our findings aid in formulating public health policies to control virus spread in regions with low-intensity COVID-19.
医护人员(HCWs)高度暴露于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染。实际的冠状病毒病(COVID-19)情况,尤其是在受影响较小的地区,尚未确定。本研究旨在评估在日本东京一家前线医院工作的 HCWs 中 SARS-CoV-2 的血清流行率。在这项横断面观察性研究中,作为强制性健康检查的一部分,对同意参加的 HCWs 进行了筛选,包括医务人员、护士和其他工作人员。记录了筛查测试结果和参与者的临床特征。在 2020 年 7 月 6 日至 8 月 21 日期间筛选的 4147 名参与者中,抗体血清流行率为 0.34%(14/4147)。高暴露风险的一线 HCWs 和低暴露风险的其他环境中的 HCWs 的血清流行率没有显著差异。在 SARS-CoV-2 血清阳性的人群中,64%(9/14)没有任何症状,并且之前没有被诊断出患有 COVID-19。总之,这项研究提供了日本 HCWs 感染和免疫状况的相关信息,日本 COVID-19 的发病率相对较低。我们的研究结果有助于制定公共卫生政策,以控制 COVID-19 低强度地区的病毒传播。